On this page
Quick Reference
Overview and Recommendations
Key Facts
- • is an oral, selective, direct inhibitor. It inhibits free factor Xa and factor Xa in the complex without requiring , reducing thrombin generation rather than directly neutralizing pre-existing thrombin.
- •Adult tablets contain 2.5 mg or 5 mg, and generic products are marketed alongside Eliquis. Tablets can be split or crushed when necessary, but feeding-tube administration and suspension preparation should follow the local product information.
- •Oral bioavailability is approximately 50%, peak plasma concentration occurs after about 3-4 hours, and the apparent terminal half-life is approximately 12 hours. Approximately 87% is protein bound, and reported urinary recovery is 24.5%-28.8%, predominantly as unchanged drug.
- •Apixaban is metabolized mainly by and CYP3A5 and is a substrate for and . Combined CYP3A4/P-glycoprotein inhibition can increase exposure, whereas combined induction can reduce exposure and weaken anticoagulation.
- •Renal impairment increases exposure, and pharmacokinetic studies found approximately threefold higher exposure with 5 mg twice daily in kidney failure on hemodialysis than with 5 mg twice daily in normal renal function. These findings do not establish a universally optimal dose.
Clinical Use
- •Confirm the indication before prescribing because apixaban regimens are not interchangeable. Adult labeled uses include stroke and systemic-embolism prevention in (AF), treatment of acute (DVT) or (PE), extended prevention of recurrent DVT or PE, and postoperative prophylaxis after hip or knee replacement in jurisdictions that retain those indications.
- •For nonvalvular AF, use 5 mg orally twice daily. Reduce to 2.5 mg orally twice daily only when at least 2 of age 80 years or older, body weight 60 kg or less, and serum creatinine 1.5 mg/dL or greater are present; do not reduce empirically for age, frailty, prior bleeding, chronic kidney disease alone, or a single borderline laboratory value.
- •Assess embolic risk with or a locally endorsed alternative, then weigh bleeding risk, renal function, frailty, adherence, interactions, life expectancy, and patient values. Do not use apixaban for a or moderate-to-severe rheumatic ; use the locally recommended vitamin K antagonist strategy instead.
- •For objectively confirmed acute DVT or PE in a haemodynamically stable adult, use 10 mg orally twice daily for 7 days, followed by 5 mg orally twice daily. Do not substitute the AF dose or the extended-prevention dose, and do not routinely precede this regimen with UFH or LMWH.
- •Direct oral anticoagulants are guideline-supported first-line treatment for most haemodynamically stable adults with acute VTE, but pregnancy, severe renal dysfunction, haemodynamic instability, unusual thrombosis, and selected cancer-associated thrombosis require individualized selection.
- •After completion of initial VTE treatment, use 2.5 mg orally twice daily for extended prevention when recurrence risk outweighs bleeding risk. The US Food and Drug Administration label includes reduction to 2.5 mg twice daily after 6 months of treatment, while local labeling and disease-specific guidance may differ.
- •For postoperative VTE prophylaxis after hip replacement, use 2.5 mg orally twice daily, commonly for 35 days. After knee replacement, use 2.5 mg orally twice daily, commonly for 12 days; verify local authorization, the surgical protocol, and secure haemostasis.
- •In active cancer-associated VTE, consider apixaban for selected patients after reviewing tumour site, mucosal involvement, bleeding risk, renal function, interactions, absorption, and patient preference. Specialist-directed LMWH or another strategy may be preferable when bleeding risk or oral treatment feasibility is unacceptable.
- •Before the first dose, confirm the indication and regimen, secure haemostasis, review all medicines and supplements, and obtain a , serum creatinine with calculated , and . Use the Cockcroft-Gault method commonly used in the supporting dosing evidence rather than substituting an unexamined estimated glomerular filtration rate.
- •For most anticoagulant switches, avoid gaps and overlap: give apixaban when the next dose of UFH, LMWH, or another DOAC would be due. Stop warfarin and start apixaban when the INR is below 2.0; when changing from apixaban to warfarin, use a therapeutic parenteral anticoagulant when the next apixaban dose would have been due until the INR is therapeutic according to local protocol.
- •For a missed dose, take it as soon as remembered on the same day and resume the twice-daily schedule; if the next dose is imminent, omit the missed dose. Do not double the next dose, and seek advice after an extra dose or vomiting soon after administration.
Safety
- •Bleeding is the principal clinically important toxicity. Ask about bruising, epistaxis, haematuria, melaena, haematemesis, heavy menstrual bleeding, falls, head trauma, dizziness, and neurological symptoms; investigate an unexplained haemoglobin fall rather than attributing it automatically to chronic disease.
- •Do not start apixaban with active pathological bleeding or clinically significant hypersensitivity to apixaban or its excipients. Evaluate recent surgery, invasive procedures, trauma, suspected gastrointestinal bleeding, intracranial hemorrhage, anaemia, thrombocytopenia, liver disease, and the patient’s ability to administer a twice-daily medicine safely.
- •Monitor clinically rather than titrating to a routine coagulation target. Reassess bleeding, thrombosis, adherence, medicines, haemoglobin, platelet count, renal function, and hepatic status; yearly renal-function review is a minimum supported by published laboratory guidance, with earlier testing when renal function or clinical status changes.
- •Routine , , and do not quantify apixaban exposure. A normal PT/INR or aPTT cannot exclude clinically relevant activity and must not be used to increase the dose or clear a patient for high-consequence surgery.
- •When an urgent result could change management, request a chromogenic calibrated specifically for apixaban. Interpret it with the dose, exact last-dose and sampling times, renal and hepatic function, interacting medicines, and clinical question; no routine therapeutic range has been established.
- •Avoid strong combined CYP3A4/P-glycoprotein inducers such as rifampin, carbamazepine, phenytoin, phenobarbital, and St John’s wort when possible; do not compensate by doubling apixaban. Strong combined inhibitors such as ketoconazole, itraconazole, posaconazole, and ritonavir-containing regimens increase exposure and bleeding risk; follow the local product label, and avoid the combination when a patient already receives 2.5 mg twice daily under US labeling.
- •Review aspirin, P2Y12 inhibitors, other anticoagulants, thrombolytics, NSAIDs, SSRIs, SNRIs, systemic corticosteroids, alcohol, and herbal products because additive bleeding or interaction risks may occur. Advise patients to avoid unsupervised aspirin, ibuprofen, naproxen, and other NSAIDs; apixaban may be taken with or without meals, and routine vitamin-K dietary restriction is unnecessary.
- •Use specialist review for severe or changing renal dysfunction, dialysis, acute kidney injury, advanced liver disease, pregnancy, children, very low body weight, extreme obesity, and active cancer. Do not stack unvalidated dose reductions; AF criteria do not define acute VTE treatment, and weight alone does not justify reducing VTE-treatment or postoperative-prophylaxis dosing.
- •For elective procedures, the American College of Chest Physicians and prospective perioperative data support interruption according to bleeding risk. Continue or omit the procedure-day dose for minimal-risk procedures; for low-to-moderate risk, omit apixaban for the day before and day of the procedure; for high-risk surgery, omit it for 2 days before and the day of surgery, then restart when haemostasis is secure.
- •For neuraxial anesthesia, spinal surgery, spinal puncture, or deep neuraxial/deep plexus block, the American Society of Regional Anesthesia and Pain Medicine recommends discontinuing apixaban for 3 days before the procedure. Do not restart while an indwelling neuraxial catheter remains in place.
- •For major or life-threatening bleeding, hold apixaban, resuscitate, control the source, and involve hematology and critical care. Consider andexanet alfa where approved and suitable; when it is unavailable, unsuitable, unaffordable, or not locally recommended, 4-factor prothrombin complex concentrate may be used at 25-50 U/kg IV or as a fixed 2,000 IU IV dose in local protocols.
- •THANZ considers andexanet alfa for life-threatening or uncontrolled bleeding when the last apixaban dose was less than 18 hours earlier and advises treatment when an urgent drug-specific level exceeds 75 ng/mL if timing is unknown. ESAIC considers levels above 50 ng/mL clinically relevant; these are guideline-dependent decision aids, not validated therapeutic cutoffs, and unstable patients should not wait for delayed testing.
- •Do not use vitamin K, protamine, routine plasma, or haemodialysis as dependable apixaban reversal strategies. Once haemostasis is secure, reassess the indication and thrombotic risk; THANZ gives a weak recommendation for resumption in most patients unless recurrent bleeding risk remains high, with a usual individualized restart window between 1 and 6 weeks.
Deep Dive — Evidence Details
Apixaban: Mechanism, Formulations, and Regulatory Uses
- ▸Apixaban inhibits factor Xa upstream of thrombin generation and does not require antithrombin.
- ▸Never substitute AF, acute-VTE, extended-prevention, or postoperative regimens.
Apixaban is an oral, selective direct inhibitor. It blocks free and prothrombinase-bound factor Xa without requiring , reducing thrombin generation and fibrin formation; unlike dabigatran, it does not directly neutralize existing thrombin [1]. Adult tablets are 2.5 mg and 5 mg; tablets may generally be split or crushed, but feeding-tube administration should follow local product information [18]. Approved adult uses include stroke/systemic-embolism prevention in , acute or treatment, extended prevention of recurrent VTE, and selected hip/knee replacement prophylaxis. Pediatric authorization is jurisdiction-dependent; the United States approved pediatric VTE use in 2025 [11]. Always match dose and duration to indication; adult authorization does not establish pediatric suitability.
Mechanism, Pharmacodynamics, and Pharmacokinetics
- ▸Peak effect occurs over hours, not immediately; twice-daily dosing reflects the approximately 12-hour half-life.
- ▸Exposure rises with renal impairment and dual CYP3A4/P-glycoprotein inhibition.
Factor Xa within the complex converts prothrombin to , amplifying fibrin formation and platelet activation. Apixaban binds the factor Xa active site, suppressing thrombin generation in a concentration-dependent manner; higher concentrations increase bleeding risk [13]. Oral bioavailability is approximately 50%, peak concentration occurs at 3-4 hours, and terminal half-life is about 12 hours. Approximately 87% is protein bound. Clearance involves CYP3A4/5 metabolism, P-glycoprotein and BCRP transport, and renal/fecal elimination; CYP3A contributes about 25% in a validated model [21]. Urinary recovery is 24.5%-28.8%, mostly unchanged drug [21]. Strong combined CYP3A4/P-glycoprotein inhibitors increase exposure, while inducers reduce it. Hemodialysis does not reliably remove apixaban; 5 mg twice daily produced approximately threefold higher exposure in kidney failure [5].
Selecting Apixaban for Atrial Fibrillation and VTE
- ▸Indication determines regimen; AF dosing cannot be substituted for acute VTE treatment.
- ▸Mechanical valves and moderate-to-severe rheumatic mitral stenosis require another strategy.
For , confirm the rhythm and exclude mechanical valves or moderate-to-severe rheumatic . Estimate embolic risk with , then balance bleeding risk, renal function, frailty, interactions, adherence, life expectancy, and patient preference. DOACs are generally preferred for eligible patients [34]. Reduce AF dosing only when at least 2 criteria are present: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL [35]. For objectively confirmed, haemodynamically stable or , apixaban is first-line for many adults: 10 mg twice daily for 7 days, then 5 mg twice daily [3][4]. Do not extrapolate to pregnancy, severe renal dysfunction, instability, unusual thrombosis, or complex cancer without specialist review. Avoid apixaban for mechanical valves, rheumatic mitral stenosis, active bleeding, or clinically significant hypersensitivity.
Apixaban Regimens by Indication and Treatment Phase
- ▸Acute VTE: 10 mg twice daily for 7 days, then 5 mg twice daily.
- ▸Extended prevention: 2.5 mg twice daily only after initial therapy.
Apixaban dosing is indication-specific. In AF, use 5 mg twice daily unless at least 2 of age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL are present; then use 2.5 mg twice daily [44]. Acute DVT/PE requires 10 mg twice daily for 7 days, followed by 5 mg twice daily; the AF reduction rule does not define VTE dosing. Extended prevention uses 2.5 mg twice daily only after adequate initial treatment, commonly after at least 6 months [48]. Postoperative prophylaxis, where authorized, is 2.5 mg twice daily: commonly 35 days after hip replacement and 12 days after knee replacement [44]. Do not empirically reduce doses for age, frailty, anaemia, or bleeding history. Reconcile local labeling, cancer guidance, renal function, and treatment phase before every prescription or transition.
Baseline Evaluation Before the First Dose
- ▸Baseline CBC, Cockcroft-Gault creatinine clearance, liver tests, medication review, and bleeding assessment are essential.
- ▸Abnormalities require investigation or specialist advice, not automatic dose reduction.
Confirm the indication, treatment phase, intended regimen, haemostasis, and ability to take twice-daily therapy. Exclude active pathological bleeding, recent significant head trauma, unstable postoperative haemostasis, unexplained anaemia, marked thrombocytopenia, severe hepatic coagulopathy, and clinically important hypersensitivity [60]. Review prior intracranial or gastrointestinal bleeding, falls, frailty, alcohol use, pregnancy potential, and all antithrombotic, NSAID, steroid, prescription, and supplement exposures. Obtain CBC with haemoglobin and platelets, serum creatinine with Cockcroft-Gault creatinine clearance, and liver tests [61][62]. Do not substitute eGFR without review. Investigate abnormalities rather than responding with unvalidated underdosing. Establish adherence, affordability, swallowing, caregiver support, and refill plans; real-world discontinuation is common [64][65].
Renal, Hepatic, Age, Weight, and Special-Population Use
- ▸Severe or changing renal/hepatic dysfunction is an evidence boundary, not a reason for automatic underdosing.
- ▸Use only locally authorized pediatric regimens; never extrapolate adult doses.
Use Cockcroft-Gault creatinine clearance and reassess when renal function changes. Patients with CrCl <30 mL/min were largely excluded from pivotal trials, so evidence is less secure [80]. In AF, follow labeled criteria rather than reducing solely for CKD; dialysis use is jurisdiction-dependent and pharmacokinetically uncertain [5][80]. Acute VTE has no validated empiric renal reduction; severe renal failure requires specialist-directed therapy. Acute kidney injury or rapidly changing renal function may require withholding or changing treatment [81]. Weight alone does not justify dose adjustment in obesity or low body weight [36][82]. In hepatic disease, Child-Pugh A generally permits use without adjustment if no coagulopathy; Child-Pugh B lacks established dosing, and Child-Pugh C should be avoided under product labeling. Pregnancy, lactation, children, active cancer, and dialysis require specialist care [2][6][83].
Starting, Switching, Interrupting, and Adhering
- ▸Use a no-gap, no-overlap strategy for most short-acting anticoagulant transitions.
- ▸Never compensate for missed doses by doubling apixaban.
Start only after confirming the indication-specific dose and secure haemostasis. Acute stable VTE can begin directly with 10 mg twice daily for 7 days, then 5 mg twice daily, without routine heparin lead-in [3]. For most switches, start apixaban when the next dose of UFH, LMWH, or another DOAC would be due; avoid overlap. From warfarin, start when INR <2.0. When switching to warfarin, overlap with a parenteral anticoagulant according to local protocol until INR is therapeutic. For a missed dose, take it the same day when remembered; otherwise omit it and resume normally, never double. Vomiting, overdose, or uncertain absorption requires clinical advice. Avoid unsupervised aspirin and NSAIDs. Do not stop abruptly without a replacement plan; refill gaps and transition errors commonly cause harm [87][88].
Drug, Food, and Herbal Interactions
- ▸Avoid strong CYP3A4/P-glycoprotein inducers; do not empirically increase apixaban.
- ▸Separate inhibitor-based dose reduction from AF criteria and acute-VTE dosing.
Strong combined CYP3A4/P-glycoprotein inhibitors, including ketoconazole, itraconazole, posaconazole, ritonavir-containing regimens, and nirmatrelvir/ritonavir, increase exposure and bleeding risk [94][96]. US labeling reduces 5- or 10-mg twice-daily doses by 50%; patients already on 2.5 mg twice daily should avoid the combination. For acute VTE, avoiding the inhibitor or choosing another anticoagulant may be safer than halving therapy. Strong inducers, rifampin, carbamazepine, phenytoin, phenobarbital, and St John’s wort, reduce exposure; avoid coadministration and never compensate by doubling [26][95]. Aspirin, P2Y12 inhibitors, NSAIDs, SSRIs/SNRIs, corticosteroids, and heavy alcohol use add pharmacodynamic bleeding risk [100-103]. Apixaban may be taken with or without food; vitamin-K dietary restrictions are unnecessary [109]. Review all supplements and herbal products.
Monitoring and Laboratory Interpretation
- ▸Monitor the patient and organ function, not an INR target.
- ▸Use drug-specific anti-factor Xa testing selectively for urgent decisions.
Routine warfarin-style monitoring is unnecessary, but review bleeding, thrombosis, adherence, dose timing, new medicines, CBC, renal function, and hepatic status [112]. Check renal function at least annually and sooner with acute illness or deterioration. PT/INR and aPTT are reagent-dependent and cannot quantify apixaban; normal results do not exclude clinically relevant activity, and aPTT may fail to detect concentrations up to 200 ng/mL [112][117]. When urgent surgery, life-threatening bleeding, overdose, severe renal dysfunction, or uncertain last dose makes exposure relevant, request an apixaban-calibrated chromogenic anti-factor Xa assay [112][114]. Interpret with dose, exact sampling time, renal/hepatic function, and interacting drugs. Peak sampling is approximately 2-4 hours after dosing; no validated routine therapeutic range exists [119][120]. Do not change dose from concentration alone.
Adverse Effects, Hemorrhage, and Thrombotic Harm
- ▸Hold apixaban and control the bleeding source; do not rely on screening coagulation tests.
- ▸Suspected thrombosis requires confirmation and exposure reconstruction, not empiric dose escalation.
Bleeding is the principal serious toxicity. Assess airway, circulation, neurological status, suspected source, last dose, renal/hepatic function, haemoglobin, platelets, and interacting medicines. Hold apixaban during clinically significant active bleeding; pursue local pressure, endoscopic, surgical, radiologic, or neurosurgical control. Nuisance bruising, epistaxis, haematuria, and heavy menstrual bleeding may signal occult disease or excessive exposure. Suspected intracranial, gastrointestinal, retroperitoneal, spinal, or major bleeding requires urgent escalation. A normal INR or aPTT does not exclude activity. Conversely, recurrent DVT, PE, or stroke requires objective confirmation and review of adherence, incorrect treatment phase, vomiting/malabsorption, organ dysfunction, and inducers; never simply double apixaban. Reversal and resumption decisions must balance bleeding against thrombotic risk [19,26,129-131].
Reversal and Emergency Management of Major Bleeding
- ▸Source control and resuscitation are primary; reversal is for major or life-threatening bleeding.
- ▸Andexanet and PCC carry thrombotic risk and should not routinely be combined.
Hold apixaban, resuscitate, obtain CBC, creatinine, liver tests, type and crossmatch, and control the source; involve hematology, critical care, and site-specific specialists. Clinically significant bleeding includes haemoglobin fall ≥20 g/L, ≥2 units red-cell transfusion, or haemodynamic instability; life-threatening bleeding involves a critical organ/compartment or refractory hypotension [134]. Do not delay treatment for drug levels; normal PT/aPTT do not exclude apixaban [134][135]. For life-threatening or uncontrolled bleeding, use andexanet alfa where approved and suitable: low dose is 400-mg bolus then 4 mg/min for 120 minutes; high dose is 800-mg bolus then 8 mg/min for 120 minutes. If unavailable or unsuitable, use 4F-PCC 25-50 U/kg IV or local fixed 2,000 IU protocol [134]. Activated charcoal may be considered within 2 hours, possibly up to 8 hours, with a protected airway. Vitamin K, protamine, routine plasma, and dialysis do not reverse apixaban.
Perioperative and Neuraxial Management
- ▸Neuraxial procedures: hold at least 72 hours.
- ▸Restart only after secure haemostasis; routine therapeutic bridging is not recommended.
Classify procedural bleeding risk and renal function. Minimal-risk procedures may continue apixaban or omit the procedure-day dose. For low-to-moderate risk, hold for approximately 2 calendar days and restart about 1 day afterward if haemostasis is secure. For high-risk surgery, hold for approximately 3 calendar days and restart about 2 days afterward [134][140]. Neuraxial, spinal, or deep plexus procedures require at least 72 hours off apixaban; do not restart with an indwelling neuraxial catheter [155]. Extend intervals for CrCl <50 mL/min, acute kidney injury, interacting inhibitors, low weight, or uncertain last dose [160]. Routine heparin bridging is unnecessary and increases bleeding; use mechanical prophylaxis when appropriate [134][154]. Urgent surgery requires immediate cessation, last-dose documentation, specialist input, and selective drug-specific anti-Xa testing. Normal PT/aPTT cannot clear a patient for high-consequence surgery.
Clinical Trial Evidence and Comparative Role
- ▸Strongest randomized support is for eligible nonvalvular AF and selected VTE populations.
- ▸Evidence becomes less certain in dialysis, advanced liver disease, severe renal dysfunction, and complex cancer.
Evidence is indication-specific. In ARISTOTLE, apixaban reduced stroke/systemic embolism versus warfarin (HR 0.79), major bleeding (HR 0.69), and all-cause mortality (HR 0.89) in eligible AF patients [167]. CARAVAGGIO found similar recurrent VTE and major bleeding versus dalteparin in cancer-associated VTE: recurrence 4.7% versus 6.2%, major bleeding 2.8% versus 2.9% [169]. RENAL-AF was underpowered in hemodialysis, so it does not establish an optimal regimen [174]. Observational comparisons often suggest less bleeding with apixaban than rivaroxaban or warfarin, but confounding limits certainty [171][178][183]. Apixaban is convenient because it is oral and does not require INR titration, but warfarin remains preferred for mechanical valves, rheumatic mitral stenosis, and some severe organ dysfunction. LMWH may be preferable when absorption, procedures, or rapid reversibility dominate.
Long-Term Follow-Up, De-escalation, and Restarting
- ▸Reassess the reason to anticoagulate before changing the dose.
- ▸Restart only after source control and individualized thrombotic-versus-bleeding assessment.
Reassess indication, thromboembolic risk, bleeding phenotype, renal/hepatic function, adherence, interactions, procedures, and patient priorities at each review. After transiently provoked VTE, confirm the provoking factor has resolved; unprovoked, recurrent, persistent-risk, and active-cancer VTE often favor extended therapy when bleeding risk permits [3]. Use 2.5 mg twice daily for extended VTE prevention only after adequate initial treatment; API-CAT supports reduced-dose therapy in selected patients with active cancer after ≥6 months, but does not mandate it [184]. AF anticoagulation after ablation follows stroke risk, not apparent rhythm control; guidance recommends at least 3 months and then risk-based continuation [88]. After GI or intracranial bleeding, correct the source and involve specialists before restarting. After surgery, resume the original indication-specific regimen only when haemostasis is secure. Document the next dose and provide written emergency and missed-dose instructions.
References
- [1]
Chen S, Shi C, Li X et al.. “Kidney injury associated with direct oral anticoagulants: a comparative study of direct thrombin inhibitors and factor Xa inhibitors based on literature and database analysis.” Renal failure (2026). PMID: 42717832 ↗
Journal Article, Comparative StudyCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics, Renal, Hepatic, Age, Weight, and Other Special-Population Use - [2]
Huang C, Li S, He J. “Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Thrombosis: An Indication-Stratified Systematic Review and Meta-Analysis of Treatment and Postoperative Prophylaxis.” Cardiovascular drugs and therapy (2026). PMID: 42622790 ↗
Journal Article, Systematic ReviewCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Renal, Hepatic, Age, Weight, and Other Special-Population Use, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban, Clinical Trial Evidence and Comparative Role of Apixaban - [3]
Hammerschlag G, Yo S, Lawton E et al.. “Contemporary anticoagulation management in pulmonary embolism.” Thrombosis research (2026). PMID: 42826568 ↗
Journal Article, ReviewCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Starting, Switching, Interrupting, and Adhering to Apixaban, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban, Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [4]
Al Yami MS. “Reduced Versus Full Lead-In Apixaban or Rivaroxaban in Acute Venous Thromboembolism: A Systematic Review.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2026). PMID: 42610841 ↗
Journal Article, Systematic ReviewCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Apixaban Regimens by Indication and Treatment Phase - [5]
Yang SH. “Apixaban Dose Selection in Kidney Failure: Reconciling Pharmacokinetics and Clinical Outcomes.” The Annals of pharmacotherapy (2026). PMID: 42670022 ↗
Journal Article, ReviewCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics, Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Renal, Hepatic, Age, Weight, and Other Special-Population Use, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [6]
Zuin M, Becattini C, Vedovati MC et al.. “Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs.” Research and practice in thrombosis and haemostasis (2026). PMID: 42620909 ↗
Journal ArticleCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Renal, Hepatic, Age, Weight, and Other Special-Population Use - [7]
Mihm AE, Hernandez KN, Sauvageau IS et al.. “Full versus abbreviated lead-in durations of apixaban and rivaroxaban after initial parenteral anticoagulation in the treatment of venous thromboembolism.” Thrombosis research (2026). PMID: 42777417 ↗
LetterCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Starting, Switching, Interrupting, and Adhering to Apixaban - [8]
Girard P, Presles E, Sanchez O et al.. “Comparative Safety and Efficacy of Apixaban and Rivaroxaban During Extended Anticoagulation for Venous Thromboembolism: A Non-randomised Post Hoc Comparison Within the RENOVE Trial.” The European respiratory journal (2026). PMID: 42919641 ↗
Journal ArticleCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Starting, Switching, Interrupting, and Adhering to Apixaban, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban, Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [9]
Damba JJ, Beradid S, Azoulay L et al.. “Trends in Oral Anticoagulant Prescribing for Atrial Fibrillation and Active Cancer in UK Primary Care.” JACC. Advances (2026). PMID: 42914750 ↗
Journal ArticleCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses - [10]
Bednarski J, Wojewódzki M, Szewczak M et al.. “Temporal Trends in Anticoagulant Prescribing in Patients with Atrial Fibrillation According to Prior Ischemic Stroke or Transient Ischemic Attack: Insights from the CRAFT Registry.” Journal of clinical medicine (2026). PMID: 42796014 ↗
Journal ArticleCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses - [11]
Abdelghani E, Thakkar M, Berthiaume J et al.. “The use of direct oral anticoagulants in children with congenital and acquired heart disease.” Frontiers in cardiovascular medicine (2026). PMID: 42630602 ↗
Journal Article, ReviewCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Renal, Hepatic, Age, Weight, and Other Special-Population Use - [12]
Saraswat A, Smith SN, Dorsch MP et al.. “Clinical decision support tool evaluation: Correction of direct oral anticoagulant dosing errors by clinical pharmacists and physicians.” Research and practice in thrombosis and haemostasis (2026). PMID: 42699097 ↗
Journal Article, Randomized Controlled TrialCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Starting, Switching, Interrupting, and Adhering to Apixaban, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [13]
Riley C, Lam K, Micale C et al.. “An Observational Study of the Effect of Concomitant Levetiracetam on Apixaban Concentrations in a Hospital Cohort.” Clinical and translational science (2026). PMID: 42681674 ↗
Journal Article, Observational StudyCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics, Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Drug, Food, and Herbal Interactions with Apixaban - [14]
Chen Q, Singer DE, Fu EL et al.. “Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced CKD Not Requiring Dialysis.” JAMA network open (2026). PMID: 42696280 ↗
Journal ArticleCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics, Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Renal, Hepatic, Age, Weight, and Other Special-Population Use, Starting, Switching, Interrupting, and Adhering to Apixaban, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [15]
Winkelmayer WC, Montez-Rath ME, He M et al.. “Initiation of Apixaban Versus Warfarin in Patients With Kidney Failure on Hemodialysis With Newly Diagnosed Atrial Fibrillation: A Target Trial Emulation.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2026). PMID: 42906734 ↗
Journal ArticleCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics, Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Renal, Hepatic, Age, Weight, and Other Special-Population Use, Starting, Switching, Interrupting, and Adhering to Apixaban - [16]
Potere N, Xu Y, Mallick R et al.. “Performance status and outcomes in patients with cancer receiving thromboprophylaxis: a subanalysis of the AVERT trial.” Cardio-oncology (London, England) (2026). PMID: 42897686 ↗
Journal ArticleCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Renal, Hepatic, Age, Weight, and Other Special-Population Use, Starting, Switching, Interrupting, and Adhering to Apixaban - [17]
Mahé I, Chidiac J, Righini M et al.. “Factors Associated With Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis.” JACC. CardioOncology (2026). PMID: 42886105 ↗
Journal ArticleCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Starting, Switching, Interrupting, and Adhering to Apixaban, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [18]
Bosch A, Berger F, Dave H et al.. “Apixaban for thromboprophylaxis in paediatric cardiology patients: Real-world data from a single institution.” Thrombosis research (2026). PMID: 42914740 ↗
Journal ArticleCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Renal, Hepatic, Age, Weight, and Other Special-Population Use - [19]
Alabdelmuhsin LS, Alwethairi MF, Alharbi D et al.. “Real-world safety and clinical outcomes of apixaban in patients with cancer and atrial fibrillation.” Frontiers in cardiovascular medicine (2026). PMID: 42798347 ↗
Journal ArticleCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [20]
Hussaini P, Larsen TL, Ghanima W et al.. “Clinical significance of symptomatic and incidental venous thromboembolism in patients with cancer treated with apixaban.” Research and practice in thrombosis and haemostasis (2026). PMID: 42898096 ↗
Journal ArticleCited in: Apixaban: Direct Factor Xa Inhibitor, Formulations, and Regulatory Uses, Starting, Switching, Interrupting, and Adhering to Apixaban, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [21]
Wang G, Lakota E, Feng B et al.. “Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling.” Journal of clinical pharmacology (2026). PMID: 42760871 ↗
Journal ArticleCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics - [22]
Hirai T, Katayama K. “Drug-Drug Interactions Between Oral Anticoagulants and Calcineurin Inhibitors in Nephrotic Syndrome for Management of Thromboembolism.” Biomedicines (2026). PMID: 42652049 ↗
Journal Article, ReviewCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics, Starting, Switching, Interrupting, and Adhering to Apixaban, Drug, Food, and Herbal Interactions with Apixaban, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [23]
Hines DM, Anupindi VR, Munnangi S et al.. “Cost comparison between apixaban and low molecular weight heparin (LMWH) among venous thromboembolism (VTE) patients with cancer.” Current medical research and opinion (2026). PMID: 42696476 ↗
Journal Article, Comparative StudyCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics - [24]
Bartoli-Abdou JK, Cohen AT, Vernon L et al.. “Comparing outcomes using low-dose apixaban and anti-Xa monitoring and vitamin K antagonists in patients with renal replacement therapy.” British journal of clinical pharmacology (2026). PMID: 42693888 ↗
Journal ArticleCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics, Renal, Hepatic, Age, Weight, and Other Special-Population Use, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban, Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [25]
Jiang FR, Shen T. “Interpreting low-dose apixaban during renal replacement therapy: From anti-Xa exposure to clinical effectiveness.” British journal of clinical pharmacology (2026). PMID: 42850880 ↗
LetterCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics - [26]
Cancellerini C, Esposto R, Caravelli A et al.. “Clinical Interactions Between Antiseizure Medications and Direct Oral Anticoagulants: A Scoping Review on Therapeutic Failures and Knowledge Gaps.” Therapeutic drug monitoring (2026). PMID: 42909474 ↗
Journal ArticleCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics, Drug, Food, and Herbal Interactions with Apixaban, What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [27]
Kim Y, Lee S, Park Y et al.. “Real-World Assessment of Direct Oral Factor Xa Inhibitors: Dosing Appropriateness, Drug Exposure, and Inter-Platform Comparability of Chromogenic Anti-Xa Assays.” Diagnostics (Basel, Switzerland) (2026). PMID: 42739156 ↗
Journal ArticleCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics - [28]
Woo KS, Kim DH, Park JS et al.. “Direct Oral Anticoagulant-Calibrated Heparin LRT Assay as a Rapid Alternative to an Anti-Factor Xa Assay for Measuring Apixaban, Edoxaban, and Rivaroxaban in Patients With Non-Valvular Atrial Fibrillation.” International journal of laboratory hematology (2026). PMID: 42836645 ↗
LetterCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics - [29]
Oh S, Nakajima Y, Onishi T et al.. “Plasma-Derived Factor VIIa/Factor X Improves Thrombin Generation Potential in a Plasma Model of Haemophilia A Supplemented With Direct Oral Anticoagulants.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42711667 ↗
Journal ArticleCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics - [30]
Noto K, Miura N, Imamura Y et al.. “Thromboelastography-Informed Andexanet Alfa Administration for Residual Apixaban Effect During Acute Aortic Dissection With Cardiopulmonary Bypass.” Journal of cardiothoracic and vascular anesthesia (2026). PMID: 42919779 ↗
Case Reports, Journal ArticleCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics - [31]
Cotiguala L, Przybylski A, Linberger L et al.. “Apixaban Use Before Kidney Transplantation: Is Reversal Necessary?” Pharmacotherapy (2026). PMID: 42736533 ↗
Journal Article, Multicenter StudyCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics, Starting, Switching, Interrupting, and Adhering to Apixaban, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [32]
Chen C, Gao T, Wan B et al.. “Apixaban in preventing portal vein thrombosis after laparoscopic splenectomy and azygoportal disconnection for cirrhosis: A single-arm trial.” Surgery (2026). PMID: 42815197 ↗
Journal ArticleCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics, Starting, Switching, Interrupting, and Adhering to Apixaban - [33]
Chiorescu Ș, Mocan M, Dinică BP et al.. “Personalized Anticoagulation in Cancer Patients: Current Evidence and Future Perspectives.” Medicina (Kaunas, Lithuania) (2026). PMID: 42796285 ↗
Journal Article, ReviewCited in: How Apixaban Produces Anticoagulation: Mechanism, Pharmacodynamics, and Pharmacokinetics, Starting, Switching, Interrupting, and Adhering to Apixaban - [34]
Scalia L, Gatto L, Agnello F et al.. “Anticoagulant Regimen for Nonvalvular Atrial Fibrillation in the Elderly and Frail Population.” The American journal of cardiology (2026). PMID: 42448258 ↗
Journal Article, ReviewCited in: Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Apixaban Regimens by Indication and Treatment Phase, Renal, Hepatic, Age, Weight, and Other Special-Population Use, Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [35]
Gouda P, Harrington J, Arps K et al.. “Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial Fibrillation.” JACC. Advances (2026). PMID: 42372348 ↗
Journal ArticleCited in: Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Apixaban Regimens by Indication and Treatment Phase, Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [36]
Ahmed F, Khan S, Shafqat M et al.. “Comparison of the Safety and Effectiveness of Apixaban Versus Rivaroxaban in Acute Venous Thromboembolism: A Propensity-Matched Real-World TriNetX Study with Obesity and Cancer Subgroup Analyses.” Journal of clinical medicine (2026). PMID: 42513325 ↗
Journal ArticleCited in: Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Renal, Hepatic, Age, Weight, and Other Special-Population Use - [37]
Parker K, Hartemink J, Choudhuri S et al.. “Development of best practice statements for anticoagulation in advanced kidney disease using the modified Delphi method.” Journal of nephrology (2026). PMID: 42583885 ↗
Journal ArticleCited in: Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism - [38]
He M, Erickson KF, Kassem H et al.. “Safety and Effectiveness of Apixaban versus Warfarin in Peritoneal Dialysis Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation.” American journal of nephrology (2026). PMID: 42412715 ↗
Journal ArticleCited in: Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Renal, Hepatic, Age, Weight, and Other Special-Population Use - [39]
Huang B, Ouyang C, Fan K et al.. “Balancing Beats and Bleeding: The Evolving Landscape of Atrial Fibrillation and Anticoagulation in the Past Two Decades.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2026). PMID: 42460738 ↗
Journal Article, ReviewCited in: Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism - [40]
Mahé I, Chapelle C, Righini M et al.. “Prognosis of Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis: Insights From the API-CAT Randomized Trial.” Circulation (2026). PMID: 42439484 ↗
LetterCited in: Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [41]
Santini P, Santagata D, Mosoni C et al.. “Full- versus Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.” Seminars in thrombosis and hemostasis (2026). PMID: 42379243 ↗
Journal ArticleCited in: Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [42]
Al-Rubaish S, Awad A, Mehros W et al.. “Efficacy and safety of apixaban versus enoxaparin in gynecologic oncology surgery: a systematic review and meta-analysis.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 42284982 ↗
Journal Article, Systematic Review, Meta-Analysis, Comparative StudyCited in: Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Clinical Trial Evidence and Comparative Role of Apixaban - [43]
Guarino ID, Nazarian S. “Early Bleeding Risk After DOAC Initiation With Concomitant Amiodarone in Older Adults With Atrial Fibrillation.” Journal of cardiovascular electrophysiology (2026). PMID: 42418755 ↗
Journal ArticleCited in: Selecting Apixaban for Atrial Fibrillation and Venous Thromboembolism, Drug, Food, and Herbal Interactions with Apixaban, Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [44]
Mandt SR, Thadathil N, Klem C et al.. “Apixaban Use in Patients with Kidney Impairment: A Review of Pharmacokinetic, Interventional, and Observational Study Data.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2024). PMID: 39102124 ↗
Journal Article, ReviewCited in: Apixaban Regimens by Indication and Treatment Phase - [45]
Gillis S, Phelan E, Pitman J et al.. “Scoping review of apixaban and rivaroxaban dosing for atrial fibrillation and venous thromboembolism in advanced chronic kidney disease.” International journal of clinical pharmacy (2026). PMID: 41733864 ↗
Journal Article, Scoping ReviewCited in: Apixaban Regimens by Indication and Treatment Phase - [46]
Kline JA, Adler DH, Alanis N et al.. “Monotherapy Anticoagulation to Expedite Home Treatment of Patients Diagnosed With Venous Thromboembolism in the Emergency Department: A Pragmatic Effectiveness Trial.” Circulation. Cardiovascular quality and outcomes (2021). PMID: 34148351 ↗
Journal Article, Pragmatic Clinical Trial, Research Support, Non-U.S. Gov'tCited in: Apixaban Regimens by Indication and Treatment Phase - [47]
Najmi T, Kong X, Kaatz S et al.. “Practice patterns of DOAC high-intensity period following parenteral lead-in treatment for venous thromboembolism.” Journal of thrombosis and thrombolysis (2026). PMID: 42418136 ↗
Journal ArticleCited in: Apixaban Regimens by Indication and Treatment Phase - [48]
McBane RD, Loprinzi CL, Zemla T et al.. “Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38537780 ↗
Journal Article, Randomized Controlled Trial, Multicenter StudyCited in: Apixaban Regimens by Indication and Treatment Phase - [49]
Mainbourg S, Cucherat M, Provencher S et al.. “Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis.” Thrombosis research (2020). PMID: 33161284 ↗
Journal Article, Meta-Analysis, Systematic ReviewCited in: Apixaban Regimens by Indication and Treatment Phase - [50]
Knueppel P, Bang SH, Troyer C et al.. “Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE).” Thrombosis research (2022). PMID: 36306678 ↗
Multicenter Study, Journal ArticleCited in: Apixaban Regimens by Indication and Treatment Phase - [51]
Xu Y, Chang AR, Inker LA et al.. “Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease.” Circulation (2023). PMID: 37681341 ↗
Journal Article, Research Support, N.I.H., ExtramuralCited in: Apixaban Regimens by Indication and Treatment Phase - [52]
Jamieson MJ, Byon W, Dettloff RW et al.. “Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2022). PMID: 35570249 ↗
Journal Article, ReviewCited in: Apixaban Regimens by Indication and Treatment Phase - [53]
Zhao Y, Guo M, Li D et al.. “Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2023). PMID: 36760080 ↗
Journal Article, ReviewCited in: Apixaban Regimens by Indication and Treatment Phase - [54]
Migliorini F, Maffulli N, Velaj E et al.. “Antithrombotic prophylaxis following total hip arthroplasty: a level I Bayesian network meta-analysis.” Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology (2024). PMID: 38194191 ↗
Systematic Review, Journal Article, Network Meta-AnalysisCited in: Apixaban Regimens by Indication and Treatment Phase - [55]
Culler MW, Lim MA, Telang SS et al.. “Delayed Administration of Apixaban and Rivaroxaban is Associated with Reduced Rates of Postoperative Bleeding Without Increasing Thromboembolic Risk Following Elective Total Hip Arthroplasty.” The Journal of arthroplasty (2026). PMID: 42001913 ↗
Journal ArticleCited in: Apixaban Regimens by Indication and Treatment Phase - [56]
Simon SJ, Patell R, Zwicker JI et al.. “Venous Thromboembolism in Total Hip and Total Knee Arthroplasty.” JAMA network open (2023). PMID: 38039005 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Apixaban Regimens by Indication and Treatment Phase - [57]
Fuat A, Ako E, Hargroves D et al.. “Inappropriate dosing of direct oral anticoagulants: findings from a clinical vignette study and physician survey.” Journal of market access & health policy (2023). PMID: 37954532 ↗
Journal ArticleCited in: Apixaban Regimens by Indication and Treatment Phase - [58]
Delesie M, Ballet A, Hillegeer C et al.. “Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care.” Clinical drug investigation (2022). PMID: 35986867 ↗
Journal ArticleCited in: Apixaban Regimens by Indication and Treatment Phase - [59]
Creeper KJ, Lenaghan G, Stockwell A et al.. “Prevalence of Potentially Inappropriate Apixaban Prescribing Within a Single-Centre Tertiary Hospital.” Australasian journal on ageing (2026). PMID: 41992940 ↗
Journal ArticleCited in: Apixaban Regimens by Indication and Treatment Phase - [60]
Dubei N, Anghel L, Benchea LC et al.. “Prevention of Gastrointestinal Bleeding in Patients Receiving Direct Oral Anticoagulants: A Narrative Review and Practical Framework for Prescribers.” Clinics and practice (2026). PMID: 42505680 ↗
Journal Article, ReviewCited in: Baseline Evaluation Before the First Apixaban Dose, Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [61]
Grant SJ, Kothari S, Gimotty PA et al.. “Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system.” Journal of thrombosis and thrombolysis (2018). PMID: 29611105 ↗
Journal ArticleCited in: Baseline Evaluation Before the First Apixaban Dose - [62]
Elenjickal EJ, Travlos CK, Marques P et al.. “Anticoagulation in Patients with Chronic Kidney Disease.” American journal of nephrology (2023). PMID: 38035566 ↗
Journal Article, ReviewCited in: Baseline Evaluation Before the First Apixaban Dose - [63]
Zou R, Tao J, Shi W et al.. “Meta-analysis of safety and efficacy for direct oral anticoagulation treatment of non-valvular atrial fibrillation in relation to renal function.” Thrombosis research (2017). PMID: 29096154 ↗
Journal Article, Meta-AnalysisCited in: Baseline Evaluation Before the First Apixaban Dose - [64]
Grymonprez M, Steurbaut S, De Backer TL et al.. “Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.” Frontiers in pharmacology (2020). PMID: 33013422 ↗
Systematic Review, Journal ArticleCited in: Baseline Evaluation Before the First Apixaban Dose - [65]
Willey V, Franchino-Elder J, Fu AC et al.. “Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population.” BMJ open (2018). PMID: 29961012 ↗
Journal Article, Observational Study, Research Support, Non-U.S. Gov'tCited in: Baseline Evaluation Before the First Apixaban Dose - [66]
Pradhan A, Shah S, Vishwakarma P et al.. “Subclinical atrial fibrillation: Implications of recent trials for guideline updates?” World journal of cardiology (2026). PMID: 41607628 ↗
Journal Article, ReviewCited in: Baseline Evaluation Before the First Apixaban Dose - [67]
Granziera S, Hasan A, Cohen AA. “Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2015). PMID: 26329910 ↗
Journal Article, Research Support, Non-U.S. Gov't, ReviewCited in: Baseline Evaluation Before the First Apixaban Dose - [68]
Sun J, Mehta HB, Segal JB et al.. “Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: A retrospective cohort study.” PLoS medicine (2025). PMID: 41004533 ↗
Journal Article, Comparative StudyCited in: Baseline Evaluation Before the First Apixaban Dose, Clinical Trial Evidence and Comparative Role of Apixaban - [69]
Floyd J, Porragas-Paseiro H, Nguyen C et al.. “Validation of the Safety and Efficacy of Apixaban as Postoperative Thromboembolism Prophylaxis for Patients with Gynecologic Malignancies.” Annals of surgical oncology (2024). PMID: 38780692 ↗
Journal Article, Validation StudyCited in: Baseline Evaluation Before the First Apixaban Dose - [70]
Pititto GN, Maraziti G, Squizzato A et al.. “Direct Oral Anticoagulants for Prevention of Venous Thromboembolism after Cancer-Related Surgery: Systematic Review and Network Meta-Analysis.” Thrombosis and haemostasis (2025). PMID: 40473263 ↗
Journal Article, Systematic Review, Meta-AnalysisCited in: Baseline Evaluation Before the First Apixaban Dose - [71]
Galvao Goncalves G, Ghanem M, Takla H et al.. “Impact of Prophylactic Apixaban for 14 Days After Sleeve Gastrectomy on Thromboembolic Events and Its Side Effects.” Obesity surgery (2025). PMID: 40632450 ↗
Journal ArticleCited in: Baseline Evaluation Before the First Apixaban Dose - [72]
Attar R, Wu A, Wojdyla D et al.. “Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials).” The American journal of cardiology (2022). PMID: 35835600 ↗
Journal ArticleCited in: Baseline Evaluation Before the First Apixaban Dose - [73]
Mazur PK, Arghami A, Macielak SA et al.. “Apixaban for Anticoagulation After Robotic Mitral Valve Repair.” The Annals of thoracic surgery (2022). PMID: 35973484 ↗
Review, Journal ArticleCited in: Baseline Evaluation Before the First Apixaban Dose - [74]
Fu W, Zhao M, Ding S et al.. “Efficacy and safety of anticoagulants on venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.” Frontiers in pharmacology (2025). PMID: 39845789 ↗
Journal Article, Systematic ReviewCited in: Baseline Evaluation Before the First Apixaban Dose - [75]
Francis CW. “Prevention of VTE in patients having major orthopedic surgery.” Journal of thrombosis and thrombolysis (2013). PMID: 23397496 ↗
Journal Article, ReviewCited in: Baseline Evaluation Before the First Apixaban Dose - [76]
Rogers KC, Finks SW. “A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).” The American journal of medicine (2018). PMID: 30053385 ↗
Journal Article, ReviewCited in: Baseline Evaluation Before the First Apixaban Dose - [77]
Huttner HB, Gerner ST, Kuramatsu JB et al.. “Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care.” Stroke (2021). PMID: 34645283 ↗
Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov'tCited in: Baseline Evaluation Before the First Apixaban Dose - [78]
Cooksey GE, Hamilton LA, McMillen JC et al.. “Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries.” Neurocritical care (2022). PMID: 35624388 ↗
Journal ArticleCited in: Baseline Evaluation Before the First Apixaban Dose - [79]
Diener HC, Halperin JL, Fox K et al.. “Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation.” International journal of clinical practice (2015). PMID: 25854636 ↗
Journal Article, Research Support, Non-U.S. Gov't, ReviewCited in: Baseline Evaluation Before the First Apixaban Dose - [80]
Sapapsap B, Aree W, Ruenroengbun N et al.. “Standard- Versus Reduced-Dose Apixaban and Vitamin K Antagonists in Patients with Atrial Fibrillation and Advanced Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.” Journal of clinical medicine (2026). PMID: 42355832 ↗
Journal Article, ReviewCited in: Renal, Hepatic, Age, Weight, and Other Special-Population Use - [81]
Merzou F, Tarantini L, Landau B et al.. “Pharmacokinetic robustness of direct oral anticoagulants vs. phenprocoumon in the emergency setting: impact of renal and hepatic impairment.” European journal of internal medicine (2026). PMID: 42364939 ↗
Journal ArticleCited in: Renal, Hepatic, Age, Weight, and Other Special-Population Use, What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [82]
de Jerphanion T, Brière O, Gautier J et al.. “Fat-free mass index and apixaban exposure in frail hospitalized older adults: An exploratory study.” The Journal of frailty & aging (2026). PMID: 42696449 ↗
Journal ArticleCited in: Renal, Hepatic, Age, Weight, and Other Special-Population Use - [83]
Brandão LR, Driscoll J, Newburger JW et al.. “Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial.” The Lancet. Haematology (2026). PMID: 42392108 ↗
Journal Article, Multicenter Study, Randomized Controlled TrialCited in: Renal, Hepatic, Age, Weight, and Other Special-Population Use - [84]
Aggarwal S, Singh V, Bhasin A et al.. “Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.” Journal of clinical medicine (2026). PMID: 42513254 ↗
Journal Article, ReviewCited in: Renal, Hepatic, Age, Weight, and Other Special-Population Use - [85]
Su YW, Pai YH, Hung YM et al.. “New oral anticoagulants and hepatocellular carcinoma among patients with HBV, HCV, and alcoholic liver diseases: a nationwide cohort study.” Hepatology international (2026). PMID: 42412361 ↗
Journal ArticleCited in: Renal, Hepatic, Age, Weight, and Other Special-Population Use - [86]
Choudhary AK. “The "obesity paradox" in dosing: a comprehensive analytical review of cockcroft-gault versus CKD-EPI for predicting clearance of narrow-therapeutic-index drugs in patients with BMI > 40 kg/m².” European journal of clinical pharmacology (2026). PMID: 42584699 ↗
Journal Article, ReviewCited in: Renal, Hepatic, Age, Weight, and Other Special-Population Use - [87]
Chang C, Lv S, Yu L et al.. “Adherence to Direct Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation: A Single-Center Retrospective Study.” Journal of cardiovascular pharmacology and therapeutics (2026). PMID: 42777254 ↗
Journal Article, Comparative StudyCited in: Starting, Switching, Interrupting, and Adhering to Apixaban, Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [88]
Liu X, Singer DE, Heist EK et al.. “Discontinuation of oral anticoagulants is common after catheter ablation in older patients with atrial fibrillation.” European heart journal open (2026). PMID: 42857529 ↗
Journal ArticleCited in: Starting, Switching, Interrupting, and Adhering to Apixaban, Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [89]
Bitar ER, Hawkins A, Cummins KC et al.. “Real-World Use and Outcomes of Post-Discharge Venous Thromboembolism Prophylaxis After Thoracic Cancer Operation.” Journal of the American College of Surgeons (2026). PMID: 42868038 ↗
Journal ArticleCited in: Starting, Switching, Interrupting, and Adhering to Apixaban - [90]
Wu C. “Apixaban Versus LMWH in CAT/VTE: A Comment on Clinical and Methodological Heterogeneity.” Cardiovascular drugs and therapy (2026). PMID: 42734692 ↗
LetterCited in: Starting, Switching, Interrupting, and Adhering to Apixaban - [91]
Zhong J, Vellema J, Yu M et al.. “Initial Direct Oral Anticoagulants Versus Warfarin After Cerebral Venous Thrombosis: A Target Trial Emulation.” Stroke (2026). PMID: 42895027 ↗
Journal ArticleCited in: Starting, Switching, Interrupting, and Adhering to Apixaban - [92]
Reny JL, Daali Y, Terrier J. “Same Target but Different Bleeding Outcomes: Insights from a Randomized Apixaban-Rivaroxaban Comparison in Patients with Acute Venous Thromboembolism.” European heart journal. Cardiovascular pharmacotherapy (2026). PMID: 42839769 ↗
Journal ArticleCited in: Starting, Switching, Interrupting, and Adhering to Apixaban, Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [93]
Crane JG, Samson R, Moore S et al.. “Apixaban as therapeutic anticoagulation in patients supported by a fully magnetically levitated left ventricular assist device.” The Journal of thoracic and cardiovascular surgery (2026). PMID: 42660443 ↗
Journal ArticleCited in: Starting, Switching, Interrupting, and Adhering to Apixaban - [94]
Concannon K, Huntsman R, Cole K et al.. “Concurrent Apixaban With Itraconazole or Posaconazole Pharmacokinetic and Clinical Outcome Evaluation in Cardiothoracic Transplant Recipients.” Clinical transplantation (2025). PMID: 40294102 ↗
Journal ArticleCited in: Drug, Food, and Herbal Interactions with Apixaban - [95]
Lenard A, Hermann SA, Stoll F et al.. “Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteers.” Frontiers in pharmacology (2025). PMID: 40290437 ↗
Journal ArticleCited in: Drug, Food, and Herbal Interactions with Apixaban - [96]
Khan MA, Daiello LA, Berry SD et al.. “Potential Drug-Drug Interactions With Nirmatrelvir/Ritonavir Among Long-Term Care Facility Residents.” Journal of the American Medical Directors Association (2026). PMID: 42413156 ↗
Journal Article, Research Support, N.I.H., ExtramuralCited in: Drug, Food, and Herbal Interactions with Apixaban - [97]
Svalastoga M, Larsen TL, Brekke J et al.. “Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism.” Frontiers in oncology (2025). PMID: 39931081 ↗
Journal ArticleCited in: Drug, Food, and Herbal Interactions with Apixaban - [98]
Terrier J, Abouir K, Gaspar F et al.. “The Impact of Dexamethasone and Prednisone on Apixaban and Rivaroxaban Exposure in COVID-19 Patients: A Physiologically Based Pharmacokinetic Modeling Study.” Clinical pharmacology and therapeutics (2024). PMID: 39535447 ↗
Journal ArticleCited in: Drug, Food, and Herbal Interactions with Apixaban - [99]
D'Amico AM, Riester MR, Leonard CE et al.. “Drug-Drug Interaction Signals for Major Bleeding in Nursing Home Residents: High-Throughput Screening of Clopidogrel and Oral Anticoagulants.” Pharmacoepidemiology and drug safety (2026). PMID: 42494112 ↗
Journal ArticleCited in: Drug, Food, and Herbal Interactions with Apixaban - [100]
Ran Y, Zhang Y, Cai Y et al.. “Association between concomitant use of direct oral anticoagulants with antidepressants and an increased risk of hemorrhage: analysis of the food and drug administration adverse event reporting system database.” Frontiers in medicine (2026). PMID: 41810231 ↗
Journal ArticleCited in: Drug, Food, and Herbal Interactions with Apixaban - [101]
Petersen SR, Bonnesen K, Larsen JB et al.. “Bleeding risk using non-steroidal anti-inflammatory drugs in anticoagulated patients with atrial fibrillation: a nationwide cohort study.” European heart journal. Quality of care & clinical outcomes (2025). PMID: 40833918 ↗
Journal Article, Multicenter StudyCited in: Drug, Food, and Herbal Interactions with Apixaban - [102]
Yao TC, Chang SM, Tsai YF et al.. “Comparative Risk of Major Bleeding With Concomitant Use of Oral Anticoagulants and Corticosteroid Bursts.” Clinical and translational science (2025). PMID: 40714858 ↗
Journal Article, Comparative Study, Research Support, Non-U.S. Gov'tCited in: Drug, Food, and Herbal Interactions with Apixaban - [103]
Cheon S, Choi YS, Kim YS et al.. “Bleeding-related interactions between DOACs and cardiovascular drugs: Insights from FDA adverse event reporting system.” The American journal of medicine (2026). PMID: 42097327 ↗
Journal ArticleCited in: Drug, Food, and Herbal Interactions with Apixaban - [104]
Dawwas GK, Lewis JD, Tedla YG et al.. “The Risk for Bleeding in Patients With Atrial Fibrillation From Concomitant Use of Apixaban or Rivaroxaban With Diltiazem Compared With Metoprolol.” Annals of internal medicine (2026). PMID: 41730211 ↗
Journal Article, Comparative StudyCited in: Drug, Food, and Herbal Interactions with Apixaban - [105]
Kolowrat S, Riley C, Lam K et al.. “Real-World Impact of Amiodarone on Apixaban Population Pharmacokinetics in Hospitalized Patients.” Clinical and translational science (2025). PMID: 41208245 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Drug, Food, and Herbal Interactions with Apixaban - [106]
Morath B, Foerster KI, Chiriac U et al.. “Effect of Amiodarone on Apixaban Exposure in Patients after Cardiac Surgery-A Population Pharmacokinetic Study.” Clinical pharmacokinetics (2025). PMID: 40474043 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Drug, Food, and Herbal Interactions with Apixaban - [107]
Ding L, Chen C, Yang Y et al.. “Risk of thromboembolic events in patients co-treated with factor Xa-inhibiting direct oral anticoagulants and anti-seizure medications: insights from pharmacovigilance data.” Expert opinion on drug safety (2025). PMID: 40302219 ↗
Journal ArticleCited in: Drug, Food, and Herbal Interactions with Apixaban - [108]
Magee MPD, Schwartz JB, McArthur A et al.. “Why patients fail to seek information on OTC product interactions with a direct-acting oral anticoagulant: perspectives on information-seeking.” BMC primary care (2025). PMID: 39984862 ↗
Journal ArticleCited in: Drug, Food, and Herbal Interactions with Apixaban - [109]
Pawłowska I, Kuźbicka K, Kowalczys A et al.. “Food-drug interactions of novel drugs used in cardiologic and diabetic patients - a PRISMA scoping review.” Frontiers in pharmacology (2026). PMID: 42124949 ↗
Journal Article, ReviewCited in: Drug, Food, and Herbal Interactions with Apixaban - [110]
Douxfils J, Adcock DM, Bates SM et al.. “2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.” Thrombosis and haemostasis (2021). PMID: 33742436 ↗
Journal Article, Practice Guideline, ReviewCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation, Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [111]
Gosselin RC, Adcock DM, Bates SM et al.. “International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.” Thrombosis and haemostasis (2018). PMID: 29433148 ↗
Journal ArticleCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [112]
Dunois C. “Laboratory Monitoring of Direct Oral Anticoagulants (DOACs).” Biomedicines (2021). PMID: 33919121 ↗
Journal Article, ReviewCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [113]
Douxfils J, Ageno W, Samama CM et al.. “Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 29193737 ↗
Journal Article, ReviewCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [114]
Wu AHB, Peacock WF. “Clinical laboratory testing of blood from patients presenting to the emergency department with acute bleeding due to factor Xa inhibitors: An unmet medical need.” Clinica chimica acta; international journal of clinical chemistry (2025). PMID: 41253216 ↗
Journal Article, ReviewCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation, Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [115]
Lucas F, Lewis J, Grandoni J et al.. “One-year retrospective analysis of anti-FXa apixaban and rivaroxaban levels demonstrates utility for management decisions in various urgent and nonurgent clinical situations.” American journal of clinical pathology (2023). PMID: 37549067 ↗
Journal ArticleCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [116]
Shaw JR, Ansell J. “A light in the dark-reframing direct oral anticoagulant pharmacokinetics and pharmacodynamics for near-patient decision-making.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42173287 ↗
Journal Article, ReviewCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [117]
Ebner M, Birschmann I, Peter A et al.. “Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.” Stroke (2017). PMID: 28775134 ↗
Journal Article, Observational StudyCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [118]
Gendron N, Cuker A, Gosselin RC et al.. “How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: communication from the ISTH SSC Subcommittee on Control of Anticoagulation.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40056991 ↗
Journal Article, Practice Guideline, Research Support, Non-U.S. Gov'tCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [119]
Thomas A, Fang MC, Kogan S et al.. “Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation.” JACC. Advances (2022). PMID: 37961076 ↗
Journal ArticleCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [120]
Schietzel S, Limacher A, Moor MB et al.. “Apixaban dosing in hemodialysis - can drug level monitoring mitigate controversies?” BMC nephrology (2024). PMID: 39385105 ↗
Journal ArticleCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [121]
Nieuwenstein T, Stoffer IP, Hellenbrand DLS et al.. “Reagent-specific anti-Xa DOAC safety cutoffs can be established using multiple LMWH-calibrated anti-Xa assays.” Clinical chemistry and laboratory medicine (2026). PMID: 42316297 ↗
Journal ArticleCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [122]
Tripodi A, Chantarangkul V, Legnani C et al.. “Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29322630 ↗
Journal ArticleCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [123]
Hollestelle MJ, Meijer P. “International external quality assessment for measurements of direct oral anticoagulants: results and recommendations.” British journal of haematology (2019). PMID: 31475356 ↗
Journal Article, Multicenter StudyCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [124]
Lanham HT, Viriyakitja W, Vestal M et al.. “Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays.” Journal of thrombosis and thrombolysis (2023). PMID: 37932587 ↗
Journal ArticleCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [125]
Costache RS, Dragomirică AS, Gheorghe BE et al.. “Oral Anticoagulation in Patients with Chronic Liver Disease.” Medicina (Kaunas, Lithuania) (2023). PMID: 36837547 ↗
Journal Article, ReviewCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [126]
Parul F, Ratnani T, Subramani S et al.. “Anticoagulation in Patients with End-Stage Renal Disease: A Critical Review.” Healthcare (Basel, Switzerland) (2025). PMID: 40565400 ↗
Journal Article, ReviewCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [127]
Verstraete A, Dreesen E, Van Thillo Q et al.. “Direct oral anticoagulant use and drug-drug interactions in transplant recipients receiving calcineurin inhibitors.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42413824 ↗
Journal ArticleCited in: What to Monitor During Apixaban Therapy: Clinical Review and Laboratory Interpretation - [128]
Vallejo MC, Kennedy LS, Dengler B et al.. “Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and the Society of Critical Care Medicine.” Neurocritical care (2026). PMID: 42786382 ↗
Journal ArticleCited in: Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [129]
Mahan CE, Grandoni J, Tsaftaridis N et al.. “Overcoming inertia in anticoagulant reversal: the current evidence gap and need for critical assessment of factor replacement strategies.” Frontiers in cardiovascular medicine (2026). PMID: 42903252 ↗
Journal Article, ReviewCited in: Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [130]
Thamgrang T, Thiwannarak P, Siricharoenthai P et al.. “Incidence and Predictors of Anticoagulant-Associated Bleeding in Patients With Venous Thromboembolism.” Journal of clinical medicine research (2026). PMID: 42730421 ↗
Journal ArticleCited in: Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban, Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [131]
Talhami E, Khader L, Salameh S. “Is a Repeat Head CT Scan Necessary After an Initial Negative Scan in Head Trauma Patients on DOAC Therapy in the Emergency Department?” Journal of clinical medicine (2026). PMID: 42881927 ↗
Journal ArticleCited in: Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [132]
Lee SH, Rymer JA, Jones WS. “Antithrombotic therapy to minimize total events after ACS or PCI in atrial fibrillation: insights from AUGUSTUS.” Current opinion in cardiology (2026). PMID: 42614044 ↗
Journal Article, ReviewCited in: Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [133]
Lv M, Zheng X, Xie H et al.. “Integrating pharmacovigilance and machine learning: bleeding signal detection and risk prediction for oral anticoagulants in cancer patients.” Research and practice in thrombosis and haemostasis (2026). PMID: 42699731 ↗
Journal ArticleCited in: Adverse Effects, Hemorrhage, and Thrombotic Harm from Apixaban - [134]
Tran HA, Merriman E, Baker R et al.. “2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri-operative and bleeding management.” Internal medicine journal (2025). PMID: 40448969 ↗
Journal Article, Practice GuidelineCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding, Perioperative and Neuraxial Management of Apixaban - [135]
Grottke O, Afshari A, Ahmed A et al.. “Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding.” European journal of anaesthesiology (2024). PMID: 38567679 ↗
Journal Article, Practice GuidelineCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [136]
Tomaselli GF, Mahaffey KW, Cuker A et al.. “2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee.” Journal of the American College of Cardiology (2020). PMID: 32680646 ↗
Journal Article, Practice Guideline, Consensus StatementCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [137]
Backus B, Beyer-Westendorf J, Body R et al.. “Management of major bleeding for anticoagulated patients in the Emergency Department: an European experts consensus statement.” European journal of emergency medicine : official journal of the European Society for Emergency Medicine (2023). PMID: 37427548 ↗
Journal Article, Consensus StatementCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [138]
Escal J, Lanoiselée J, Poenou G et al.. “Latest advances in the reversal strategies for direct oral anticoagulants.” Fundamental & clinical pharmacology (2024). PMID: 38350629 ↗
Journal Article, ReviewCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [139]
Pozzi A, Lucà F, Gelsomino S et al.. “Coagulation Tests and Reversal Agents in Patients Treated with Oral Anticoagulants: The Challenging Scenarios of Life-Threatening Bleeding and Unplanned Invasive Procedures.” Journal of clinical medicine (2024). PMID: 38730979 ↗
Journal Article, ReviewCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [140]
Douketis JD, Spyropoulos AC. “Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review.” JAMA (2024). PMID: 39133476 ↗
Journal Article, ReviewCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding, Perioperative and Neuraxial Management of Apixaban - [141]
Neumann MA, Sieg N, Garcia Borrega J et al.. “[Overdosing of direct oral anticoagulants].” Medizinische Klinik, Intensivmedizin und Notfallmedizin (2024). PMID: 38916655 ↗
Journal Article, Review, Case Reports, English AbstractCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [142]
Frol S, Oblak JP, Šabovič M et al.. “Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data.” CNS drugs (2024). PMID: 38396232 ↗
Journal ArticleCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [143]
Dobesh PP, Fermann GJ, Christoph MJ et al.. “Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.” Research and practice in thrombosis and haemostasis (2023). PMID: 37753225 ↗
Journal ArticleCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [144]
Panos NG, Jones GM, Cook AM et al.. “Reversal of Factor Xa Inhibitor-Related Intracranial Hemorrhage: A Multicenter, Retrospective, Observational Study Comparing the Efficacy and Safety of Andexanet and Prothrombin Complex Concentrates.” Critical care medicine (2025). PMID: 40172261 ↗
Journal Article, Multicenter Study, Observational Study, Comparative StudyCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [145]
Estroff JM, Devlin J, Hoteit L et al.. “Four-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study.” The journal of trauma and acute care surgery (2024). PMID: 38685190 ↗
Journal Article, Multicenter Study, Comparative StudyCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [146]
Schulman S, Bhagirath V, Chan N et al.. “Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39002730 ↗
Journal ArticleCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding, Perioperative and Neuraxial Management of Apixaban - [147]
Crawley RM, Sheikh-Taha M. “Comparison of activated and 4-factor prothrombin complex concentrates for reversal of apixaban- and rivaroxaban-associated major bleeding.” Journal of thrombosis and thrombolysis (2026). PMID: 41525014 ↗
Journal Article, Comparative StudyCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [148]
Shamiea M, Osnis A, Kashoua A et al.. “Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures.” Transfusion (2026). PMID: 41928406 ↗
Journal Article, Observational StudyCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [149]
Abraham NS, Barkun AN, Sauer BG et al.. “American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period.” The American journal of gastroenterology (2022). PMID: 35297395 ↗
Journal Article, Practice Guideline, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov'tCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [150]
Frontera JA, Lewin JJ, Rabinstein AA et al.. “Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.” Neurocritical care (2016). PMID: 26714677 ↗
Journal Article, ReviewCited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [151]
Markovic N, Budde E, Evans CT et al.. “Time to hemostatic agent administration increases mortality in veterans with factor Xa inhibitor-related intracranial hemorrhage.” The American journal of emergency medicine (2025). PMID: 40907273 ↗
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.Cited in: Reversal and Emergency Management of Apixaban-Associated Major Bleeding - [152]
Levy JH, Mamoun N. “Direct oral anticoagulants and their antagonists in perioperative practice.” Current opinion in anaesthesiology (2023). PMID: 37314165 ↗
Review, Journal ArticleCited in: Perioperative and Neuraxial Management of Apixaban - [153]
Albaladejo P, Bonhomme F, Blais N et al.. “Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015.” Anaesthesia, critical care & pain medicine (2016). PMID: 27659969 ↗
Journal Article, Practice GuidelineCited in: Perioperative and Neuraxial Management of Apixaban - [154]
Shaw JR, Kaplovitch E, Douketis J. “Periprocedural Management of Oral Anticoagulation.” The Medical clinics of North America (2020). PMID: 32505262 ↗
Journal Article, ReviewCited in: Perioperative and Neuraxial Management of Apixaban - [155]
Kim KS, Song JW, Soh S et al.. “Perioperative management of patients receiving non-vitamin K antagonist oral anticoagulants: up-to-date recommendations.” Anesthesia and pain medicine (2020). PMID: 33329805 ↗
Journal Article, ReviewCited in: Perioperative and Neuraxial Management of Apixaban - [156]
Sherwood JR, Parsons A, Al Jammala H et al.. “Perioperative Management of Oral Anticoagulation in Patients with Venous Thromboembolism.” The Medical clinics of North America (2025). PMID: 40500091 ↗
Journal Article, ReviewCited in: Perioperative and Neuraxial Management of Apixaban - [157]
Merli GJ, Kraft WK, Eraso LH et al.. “Apixaban Discontinuation for Invasive Or major Surgical procedures (ADIOS): A prospective cohort study.” Vascular medicine (London, England) (2021). PMID: 34809507 ↗
Journal Article, Observational Study, Research Support, Non-U.S. Gov't, Research Support, N.I.H., ExtramuralCited in: Perioperative and Neuraxial Management of Apixaban - [158]
Cappelleri G, Fanelli A. “Use of direct oral anticoagulants with regional anesthesia in orthopedic patients.” Journal of clinical anesthesia (2016). PMID: 27290980 ↗
Journal Article, ReviewCited in: Perioperative and Neuraxial Management of Apixaban - [159]
Tafur AJ, Clark NP, Spyropoulos AC et al.. “Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study.” Journal of the American Heart Association (2020). PMID: 32969288 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Perioperative and Neuraxial Management of Apixaban - [160]
Shaw JR, Li N, Vanassche T et al.. “Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure.” Blood advances (2020). PMID: 32756938 ↗
Journal Article, Research Support, Non-U.S. Gov'tCited in: Perioperative and Neuraxial Management of Apixaban - [161]
Lee SR, Lee KY, Park JS et al.. “Perioperative Factor Xa Inhibitor Discontinuation for Patients Undergoing Procedures With Minimal or Low Bleeding Risk.” JAMA network open (2025). PMID: 39918817 ↗
Journal Article, Multicenter Study, Research Support, Non-U.S. Gov'tCited in: Perioperative and Neuraxial Management of Apixaban - [162]
Pernod G, Albaladejo P, Godier A et al.. “Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.” Archives of cardiovascular diseases (2013). PMID: 23810130 ↗
Journal Article, Practice GuidelineCited in: Perioperative and Neuraxial Management of Apixaban - [163]
Baker RM, Selby R, Moffat KA et al.. “Investigating interassay variability between direct oral anticoagulant calibrated anti-factor Xa assays: a substudy of the perioperative anticoagulation use for surgery evaluation (PAUSE) trial.” Research and practice in thrombosis and haemostasis (2025). PMID: 40636904 ↗
Journal ArticleCited in: Perioperative and Neuraxial Management of Apixaban - [164]
Sukumar S, Cabero M, Tiu S et al.. “Anti-factor Xa activity assays of direct-acting oral anticoagulants during clinical care: An observational study.” Research and practice in thrombosis and haemostasis (2021). PMID: 34013157 ↗
Journal ArticleCited in: Perioperative and Neuraxial Management of Apixaban - [165]
Boissier E, Senage T, Babuty A et al.. “Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels.” Anesthesia and analgesia (2021). PMID: 32833716 ↗
Journal Article, Multicenter Study, Validation StudyCited in: Perioperative and Neuraxial Management of Apixaban - [166]
Lessire S, Dincq AS, Siriez R et al.. “Assessment of low plasma concentrations of apixaban in the periprocedural setting.” International journal of laboratory hematology (2020). PMID: 32297711 ↗
Clinical Trial, Journal ArticleCited in: Perioperative and Neuraxial Management of Apixaban - [167]
Powell EM, Gungabissoon U, Tazare J et al.. “Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation study.” PLoS medicine (2024). PMID: 39207948 ↗
Journal Article, Comparative Study, Research Support, Non-U.S. Gov'tCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [168]
Himmelreich JCL, Virdone S, Camm AJ et al.. “Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry.” Open heart (2025). PMID: 39832940 ↗
Journal Article, Multicenter Study, Observational Study, Comparative StudyCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [169]
Cohen AT, Creeper KJ, Alikhan R et al.. “Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer.” Thrombosis and haemostasis (2024). PMID: 38196077 ↗
Journal Article, Randomized Controlled Trial, Multicenter Study, Comparative Study, Equivalence TrialCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [170]
Arce-Huamani MA, Barboza JJ, Martínez-Herrera JF et al.. “Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.” Medicina (Kaunas, Lithuania) (2023). PMID: 37893585 ↗
Meta-Analysis, Systematic Review, Journal ArticleCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [171]
Fredman D, McNeil R, Eldar O et al.. “Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies.” Journal of thrombosis and thrombolysis (2023). PMID: 38127261 ↗
Systematic Review, Journal Article, Meta-Analysis, Comparative StudyCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [172]
Ibrahim A, Shalabi L, Zreigh S et al.. “Efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: A meta-analysis with trial sequential analysis and reconstructed time-to-event data.” Thrombosis research (2025). PMID: 40957133 ↗
Journal Article, Meta-AnalysisCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [173]
Bilal AR, Umar SA, Arfin SMW et al.. “Efficacy and safety of reduced-dose versus full-dose DOACs in extended treatment of VTE: A systematic review and meta-analysis.” Journal of thrombosis and thrombolysis (2025). PMID: 40879867 ↗
Journal Article, Systematic Review, Meta-AnalysisCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [174]
Pokorney SD, Chertow GM, Al-Khalidi HR et al.. “Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.” Circulation (2022). PMID: 36335914 ↗
Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., ExtramuralCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [175]
Hanke P, Domingo ME, Salanio G et al.. “Apixaban versus warfarin for treatment of venous thromboembolism in patients with severe renal impairment: a multicenter study.” Journal of thrombosis and thrombolysis (2025). PMID: 39987314 ↗
Journal Article, Multicenter Study, Comparative StudyCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [176]
Almajdi A, Almutairi S, Alharbi M. “Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: A systematic review and meta-analysis.” Thrombosis research (2023). PMID: 37419006 ↗
Journal Article, Systematic Review, Meta-AnalysisCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [177]
Chiv R, Beradid S, Suissa S et al.. “Effectiveness and Safety of Edoxaban Compared With Apixaban in Elderly Patients With Nonvalvular Atrial Fibrillation: A Real-World Population-Based Cohort Study.” Stroke (2024). PMID: 38511316 ↗
Journal Article, Comparative StudyCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [178]
Shurrab M, Austin PC, Jackevicius CA et al.. “Comparative effectiveness and safety of apixaban and rivaroxaban in older patients with atrial fibrillation: A population-based cohort study.” Heart rhythm (2024). PMID: 38878942 ↗
Journal Article, Comparative Study, Multicenter Study, Research Support, Non-U.S. Gov'tCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [179]
Miratashi Yazdi SA, Pezeshki PS, Zafarghandi MR. “Apixaban versus enoxaparin for venous thromboembolism prophylaxis after total gastrectomy in patients with gastric cancer: a randomized controlled trial.” International journal of surgery (London, England) (2025). PMID: 41231638 ↗
Journal Article, Randomized Controlled Trial, Comparative StudyCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [180]
Simon TG, Singer DE, Zhang Y et al.. “Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort Study.” Annals of internal medicine (2024). PMID: 38976880 ↗
Journal Article, Comparative Study, Research Support, N.I.H., ExtramuralCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [181]
Xu Y, Ballew SH, Chang AR et al.. “Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease.” Journal of the American Heart Association (2024). PMID: 39119973 ↗
Journal Article, Comparative Study, Research Support, N.I.H., ExtramuralCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [182]
Ma F, Xu W, Chen J et al.. “Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis.” European journal of clinical pharmacology (2023). PMID: 37310479 ↗
Systematic Review, Journal Article, Network Meta-AnalysisCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [183]
Dawwas GK, Cuker A. “Comparative effectiveness and safety of rivaroxaban with other oral anticoagulants in older adults with nonvalvular atrial fibrillation: population-based analysis in response to updated Beers Criteria.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39442621 ↗
Journal Article, Comparative StudyCited in: Clinical Trial Evidence and Comparative Role of Apixaban - [184]
Mahé I, Happe F, Monreal M et al.. “API-CAT investigators' decisions on anticoagulation following extended treatment for cancer-associated thrombosis.” European heart journal. Cardiovascular pharmacotherapy (2026). PMID: 42361291 ↗
Journal Article, Multicenter Study, Randomized Controlled TrialCited in: Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [185]
Li SY, Glauser G, Gonugunta N et al.. “Direct oral anticoagulant resumption patterns after traumatic subdural hemorrhage in atrial fibrillation: A multicenter cohort study.” Clinical neurology and neurosurgery (2026). PMID: 42330587 ↗
Journal Article, Multicenter StudyCited in: Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [186]
Triantafyllidou M, Stamellou E, Roumeliotis S et al.. “Anticoagulation Management in Hemodialysis Patients with Atrial Fibrillation: A Clinical Dilemma.” Current vascular pharmacology (2026). PMID: 42003213 ↗
Journal ArticleCited in: Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [187]
Hines DM, Subash R, Latremouille-Vian D et al.. “Plain language summary looking at the impact of increased patient out-of-pocket costs on stopping oral anticoagulant treatment among Medicare beneficiaries with atrial fibrillation treated with apixaban.” Current medical research and opinion (2026). PMID: 42190139 ↗
Journal ArticleCited in: Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [188]
Lutsey PL, Walker RF, Adrianzen-Herrera D et al.. “Oral Anticoagulants and Risk of Bleeding and Death in Cancer-Associated Venous Thromboembolism.” JACC. Advances (2026). PMID: 42206789 ↗
Journal ArticleCited in: Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [189]
Aghakouchakzadeh M, Kakavand H, Goldberg AJ et al.. “Thrombosis Across Female-Specific Malignancies: From Chemotherapy-Driven Risk to Prophylaxis and Drug Interactions.” Pharmacotherapy (2026). PMID: 41998827 ↗
Journal Article, ReviewCited in: Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [190]
Ebell MH, Grad R. “Top 20 Research Studies of 2025 for Primary Care Physicians.” American family physician (2026). PMID: 42789649 ↗
Journal Article, ReviewCited in: Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation - [191]
Chen Q, Singer D, Yang CT et al.. “Anticoagulation Outcomes in Nursing Home Residents With Atrial Fibrillation and ADL Disability.” JAMA network open (2026). PMID: 42832198 ↗
Journal ArticleCited in: Long-Term Follow-Up, De-escalation, and Restarting Anticoagulation